Johnson & Johnson Q1 2025 earnings summary

Johnson & Johnson reported first-quarter 2025 results with steady operational growth across both its Innovative Medicine and MedTech segments, along with updates to its full-year guidance following the acquisition of Intra-Cellular Therapies.

key financial highlights
- reported sales: $21.9 billion, up 2.4 percent
- operational sales growth: 4.2 percent
- adjusted operational sales growth: 3.3 percent
- reported earnings per share: $4.54 (includes reversal of special charges)
- adjusted EPS: $2.77, up 2.2 percent year over year
- free cash flow: approximately $3.4 billion

segment performance
- innovative medicine sales reached $13.9 billion, growing 4.2 percent operationally. key growth drivers were oncology drugs (darzalex, carvykty, rybrevant/lazcluze), immunology treatments (tremfya, simponi), neuroscience product (spravato), and xarelto. stelara declines weighed on immunology growth.
- medtech sales totaled $8.0 billion, up 4.1 percent operationally. growth was led by cardiovascular products (abiomed) and wound closure systems. sales in spine, sports medicine, and other orthopaedics declined.

geographic performance
- u.s. sales were $12.3 billion, up 5.9 percent
- international sales were $9.6 billion, down 1.8 percent reported but up 2.1 percent operationally

updated full-year 2025 guidance
- operational sales forecast raised to $91.6 billion to $92.4 billion (3.3 to 4.3 percent growth)
- adjusted EPS guidance maintained at $10.50 to $10.70 (6.2 percent midpoint growth)
- guidance reflects contribution from intra-cellular therapies acquisition and related dilution, as well as foreign exchange impacts

product pipeline and regulatory milestones
- tremfya approved in the u.s. for crohn's disease
- rybrevant and darzalex subcutaneous regimens approved in europe
- rybrevant/lazcluze demonstrated strong overall survival benefit in lung cancer
- icotrokinra showed promising results in psoriasis and ulcerative colitis
- clinical trials initiated for ottava soft tissue robotic surgery system
- nipocalimab received fast track designation for sjögren’s disease and continued positive trial results in generalized myasthenia gravis

other corporate updates
- completion of intra-cellular therapies acquisition
- announced over $55 billion in u.s. investments over four years
- named darren snellgrove as vice president of investor relations
- continued defense strategy in talc-related legal matters

johnson & johnson delivered consistent operational performance while progressing its pipeline and strategic goals. despite currency headwinds and acquisition-related impacts, the company reaffirmed its growth outlook and continues to invest in its core areas of innovation.

Johnson & Johnson Increases Dividend for 63rd Consecutive Year

Johnson & Johnson announced a 4.8% increase in its quarterly dividend, raising it from $1.24 to $1.30 per share. This marks the company’s 63rd consecutive year of dividend growth.

With the new rate, the annual indicated dividend rises from $4.96 to $5.20 per share. The next dividend will be paid on June 10, 2025, to shareholders of record as of May 27, 2025. The ex-dividend date is also May 27, 2025.

Johnson & Johnson emphasized its continued focus on healthcare innovation through its Innovative Medicine and MedTech divisions.

Johnson & Johnson MedTech Completes First Surgeries with OTTAVA Robotic System

Johnson & Johnson MedTech announced the successful completion of the first clinical cases using its OTTAVA Robotic Surgical System. These milestone procedures, performed by Dr. Erik Wilson at Memorial Hermann–Texas Medical Center, involved Roux-en-Y gastric bypass surgery and mark the system’s entry into clinical evaluation.

OTTAVA is designed as a multi-specialty robotic platform capable of supporting a broad range of complex soft-tissue procedures. The current clinical trial aims to generate data supporting the system’s use in upper abdominal general surgeries, including gastric sleeve, small bowel resection, and hiatal hernia repair. Upon completion, the company plans to pursue De Novo authorization from the U.S. FDA.

According to Johnson & Johnson, OTTAVA integrates surgical tools powered by Ethicon expertise and is built to connect with the Polyphonic digital ecosystem. The system is not yet approved for commercial use.

Hani Abouhalka, Company Group Chairman, Surgery, emphasized the innovation's potential to raise the standard of surgical care. Chief Scientific Officer Peter Schulam highlighted the importance of clinical evidence in advancing minimally invasive robotic surgery.

OTTAVA received FDA Investigational Device Exemption in late 2024 and continues to represent a significant development within Johnson & Johnson’s broader MedTech surgical portfolio. For more details, visit [thenext.jnjmedtech.com/surgicalrobotics](http://thenext.jnjmedtech.com/surgicalrobotics).

Johnson & Johnson Reports Promising Results for Psoriasis Drug Icotrokinra in Adolescents

Johnson & Johnson announced on April 10, 2025, that its investigational oral therapy icotrokinra (JNJ-2113) showed high efficacy and a favorable safety profile in adolescents with moderate-to-severe plaque psoriasis. Data from the Phase 3 ICONIC-LEAD trial revealed that 75% of adolescents achieved completely clear skin (IGA 0) after 24 weeks of treatment with the once-daily pill.

In the same period, 86.4% achieved clear or almost clear skin (IGA 0/1), and 88.6% showed a 90% improvement in the Psoriasis Area and Severity Index (PASI 90). Additionally, 63.6% reached PASI 100, indicating full skin clearance. Adverse events were reported in 50% of patients on icotrokinra, compared to 73% on placebo, with no new safety issues identified.

Icotrokinra is a first-in-class oral peptide that selectively blocks the IL-23 receptor and is part of Johnson & Johnson’s broader ICONIC clinical program targeting both plaque psoriasis and psoriatic arthritis. The study included both adolescents and adults, marking the first registrational trial to simultaneously assess a systemic therapy across these groups.

The company emphasized the importance of early and effective treatment options for younger patients and highlighted icotrokinra’s potential to provide a convenient oral alternative with strong clinical outcomes.

Johnson & Johnson Reports Positive Long-Term Results for Nipocalimab in Generalized Myasthenia Gravis

Johnson & Johnson announced encouraging new data from the Phase 3 Vivacity-MG3 study and its open-label extension evaluating nipocalimab for the treatment of generalized myasthenia gravis (gMG). The findings show sustained improvements in patient symptoms and reduced immunoglobulin G (IgG) antibody levels over an 18-month period.

Key highlights include:
- Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in muscle strength and daily function, with results sustained for up to 84 weeks, and in some cases, up to 128 weeks.
- A significant proportion (45%) of patients using steroids at the start of the open-label phase were able to reduce or discontinue their steroid dosage.
- During the 24-week double-blind phase, patients receiving nipocalimab were four times more likely to maintain improvement in muscle strength (as measured by QMG scores) than those on placebo.

Nipocalimab also demonstrated a favorable safety profile throughout the trial phases. The company presented these findings at the American Academy of Neurology (AAN) 2025 Meeting, underscoring the potential of nipocalimab as a long-term treatment option for gMG.

The investigational monoclonal antibody targets the FcRn receptor to reduce circulating IgG autoantibodies. It has received multiple designations from the FDA and EMA, including Fast Track, Orphan Drug, Breakthrough Therapy, and Priority Review for various autoimmune and maternal-fetal conditions.

The study strengthens Johnson & Johnson’s positioning in the autoantibody disease space and supports ongoing efforts to bring new, durable treatments to patients with chronic, debilitating diseases like gMG.

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Johnson & Johnson Announces TREMFYA® Achieves Key Phase 3b Milestones in Psoriatic Arthritis Treatment

Johnson & Johnson announced on April 4, 2025, that TREMFYA (guselkumab) met key clinical endpoints in its Phase 3b APEX study for adults with active psoriatic arthritis (PsA). At week 24, the treatment showed significant reductions in both the signs and symptoms of PsA, as well as in the progression of structural joint damage, compared to placebo.

TREMFYA is the first and only IL-23 inhibitor to demonstrate this dual benefit. It is a fully-human monoclonal antibody that not only blocks IL-23 but also binds to CD64, a receptor on immune cells that produce IL-23—a key driver of immune-mediated diseases like PsA.

In the APEX study, patients treated with TREMFYA showed significantly less radiographic progression, as measured by the PsA modified van der Heijde-Sharp (vdH-S) score, which evaluates joint space narrowing and erosions. The safety profile remained consistent with previous data, with no new safety signals identified.

According to Terence Rooney, Vice President and Rheumatology Disease Area Leader at Johnson & Johnson Innovative Medicine, these findings highlight the importance of addressing both inflammation and structural damage early in treatment to preserve long-term joint health.

The APEX study includes a long-term extension to assess sustained outcomes over three years. Full results are being prepared for presentation at upcoming medical congresses.

Johnson & Johnson Announces Bankruptcy Court Denial of Red River Talc LLC Plan
New Brunswick, NJ – March 31, 2025 – Johnson & Johnson (NYSE: JNJ) disclosed in a Form 8-K filing that the U.S. Bankruptcy Court for the Southern District of Texas has denied the confirmation of the prepackaged bankruptcy plan proposed by its subsidiary, Red River Talc LLC.

As a result of the court’s decision, the company announced it will reverse approximately $7 billion from previously reserved amounts that were intended for bankruptcy resolution efforts.

Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced the completion of its merger with Johnson & Johnson following the approval of an agreement originally signed on January 10, 2025. Under the terms of the merger agreement, Intra-Cellular became a wholly owned subsidiary of Johnson & Johnson through a cash transaction valued at approximately $14.6 billion.

Shareholders of Intra-Cellular received $132.00 per share in cash for each outstanding common share. The deal also included the conversion of outstanding stock options and equity awards into cash equivalents, based on the same $132 per share valuation.

All shares of Intra-Cellular common stock ceased trading on the Nasdaq Global Select Market as of April 2, 2025, and the company has initiated the process to deregister its securities with the SEC. As part of the transaction, all previous Intra-Cellular directors resigned and were replaced by the directors of the merger subsidiary.

The company’s certificate of incorporation and bylaws were also amended and restated in accordance with the terms of the merger.

This acquisition marks a significant addition to Johnson & Johnson’s neuroscience and psychiatry pipeline, bringing Intra-Cellular’s late-stage therapies and research into the Johnson & Johnson fold.

Johnson & Johnson Acquires Intra-Cellular Therapies, Expands Mental Health Portfolio

Johnson & Johnson has finalized its acquisition of Intra-Cellular Therapies, Inc., bringing the mental health drug CAPLYTA® (lumateperone) into its portfolio. CAPLYTA® is the only FDA-approved treatment for depressive episodes associated with bipolar I and II disorders as both a monotherapy and adjunctive therapy. It’s also approved for schizophrenia in adults. A supplemental application for its use in major depressive disorder is under FDA review.

This acquisition is expected to strengthen J&J’s neuroscience capabilities and support its long-term sales growth with CAPLYTA® projected to exceed $5 billion in peak annual sales. The deal also includes ITI-1284, a promising drug in Phase 2 trials for generalized anxiety disorder and Alzheimer’s-related psychosis.

Johnson & Johnson estimates an additional $0.7 billion in sales for 2025 due to this acquisition, although a slight EPS dilution of $0.25 is expected for the year. Integration of Intra-Cellular Therapies into J&J Innovative Medicine has already begun, and its stock has ceased trading on NASDAQ.

The announcement includes safety warnings and prescribing information for CAPLYTA®, as well as forward-looking statements that highlight potential risks and uncertainties involved in the acquisition and product development.

Johnson & Johnson's RYBREVANT and LAZCLUZE Combination Significantly Extends Survival in EGFR-Mutated Lung Cancer Patients, Surpassing Osimertinib

Johnson & Johnson announced on March 26, 2025, that its combination therapy of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) delivered a significant and unprecedented overall survival benefit compared to osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The findings, presented at the 2025 European Lung Cancer Congress, came from the Phase 3 MARIPOSA trial.

At a median follow-up of 37.8 months, the median overall survival for the RYBREVANT plus LAZCLUZE group had not yet been reached, with projections indicating a survival extension of over one year compared to osimertinib, whose median OS was 36.7 months. At the 3.5-year mark, 56 percent of patients receiving the combination were still alive, compared to 44 percent on osimertinib. The hazard ratio was 0.75, with a nominal p-value under 0.005.

The combination also showed benefits across several secondary endpoints, including intracranial progression-free survival, duration of response, overall response rate, and notably, time to symptomatic progression—43.6 months versus 29.3 months with osimertinib. This underscores not only survival improvement but prolonged quality of life.

Safety data showed no new concerns, with adverse events consistent with prior findings. Most occurred early in treatment. The company noted that proactive management in the first four months, including prophylactic measures, could help reduce the risk of skin reactions, infusion-related events, and venous thromboembolism.

RYBREVANT plus LAZCLUZE is already approved in the US, Europe, and other regions for first-line treatment of EGFR-mutated NSCLC. The overall survival data will be submitted to global health authorities for potential updates to labeling and treatment guidelines.

The MARIPOSA study enrolled 1,074 patients and continues to track additional endpoints. Johnson & Johnson emphasized that the data marks a potential shift in the standard of care, offering new hope for patients facing EGFR-mutant NSCLC.

Johnson & Johnson Showcases Promising Nipocalimab Data for gMG at AAN 2025

On March 26, 2025, Johnson & Johnson announced new clinical and real-world data for nipocalimab in the treatment of generalized myasthenia gravis (gMG), ahead of its presentation at the American Academy of Neurology Annual Meeting (April 5–9, 2025). The data reinforce the drug’s potential to deliver long-term disease control for antibody-positive gMG patients and highlight critical unmet needs in the current treatment landscape.

Phase 3 results from the Vivacity-MG3 trial demonstrated sustained improvement in muscle strength and symptom control using both QMG and MG-ADL scores. Patients treated with nipocalimab showed meaningful and durable clinical benefits, which were further supported by findings from the study's open-label extension. Johnson & Johnson filed a Biologics License Application for nipocalimab in August 2024, which is now under U.S. FDA Priority Review.

Additional studies presented at AAN 2025 shed light on challenges faced by patients living with gMG, particularly pregnant women and those using oral corticosteroids. Real-world evidence indicated variability in antibody testing and identified socioeconomic disparities in diagnostic practices. Patient-reported data also revealed that many individuals with gMG experience uncontrolled disease, with factors such as living alone and comorbid mental health conditions contributing to exacerbations.

Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is being studied across multiple autoantibody-related diseases and has received multiple FDA designations for rare and maternal-fetal conditions. Johnson & Johnson emphasized its ongoing commitment to advancing immunoselective therapies and improving care for diverse patient populations affected by autoantibody diseases.

Johnson & Johnson MedTech Launches DUALTO Energy System for Surgical Procedures

On March 25, 2025, Johnson & Johnson MedTech announced the launch of the DUALTO Energy System, a new electrosurgical generator designed to support a wide range of surgical procedures. The system integrates monopolar, bipolar, ultrasonic, and advanced bipolar energy delivery into a single platform, suitable for both open and minimally invasive surgeries. It recently received 510(k) clearance from the U.S. Food and Drug Administration.

The DUALTO system will be showcased at the AORN Global Surgical Conference & Expo in Boston in April. Designed to enhance efficiency in operating rooms, the system features a user-friendly touchscreen, adaptive tissue technology for precision, and a double configuration that allows two surgeons to work simultaneously. It also connects to the Polyphonic Fleet software, which aids in equipment management and remote support.

The launch reflects Johnson & Johnson’s continued commitment to innovation in surgical technologies, with the DUALTO system also being developed for future compatibility with the OTTAVA Robotic Surgical System. The company emphasizes that this new solution will streamline workflows, reduce setup time, and improve surgical outcomes.

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

Johnson & Johnson announced plans to invest over 55 billion dollars in the United States over the next four years, marking a 25 percent increase compared to the previous four years. The investment includes four new manufacturing facilities, starting with a 2 billion dollar high-tech biologics plant in North Carolina, expected to support 5,000 construction jobs and create over 500 permanent positions.

The investment will also go toward expanding research and development, advancing technologies in areas such as oncology, immunology, and neuroscience, and improving drug discovery processes. Johnson & Johnson estimates its total U.S. economic impact will exceed 100 billion dollars annually.

Johnson & Johnson announced new data from its oncology pipeline at the 2025 European Lung Cancer Congress (ELCC), highlighting the Phase 3 MARIPOSA study results. The study showed that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) significantly improves overall survival compared to osimertinib in first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). This breakthrough could extend patient survival by over a year, reshaping treatment expectations.

Additional findings include the Phase 2 COCOON study, which evaluates a proactive dermatologic regimen for patients receiving RYBREVANT, and the PALOMA-2 study, which explores switching to a subcutaneous formulation of amivantamab. These advancements reinforce Johnson & Johnson’s commitment to developing innovative, chemotherapy-free regimens that enhance patient outcomes and quality of life.

Johnson & Johnson announced new data from its oncology pipeline at the 2025 European Lung Cancer Congress, highlighting the Phase 3 MARIPOSA study results. The study showed that RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperformed the standard-of-care treatment, osimertinib, for patients with EGFR-mutated non-small cell lung cancer. The combination therapy is projected to improve overall survival by more than a year, offering a major breakthrough in first-line treatment.

Additional findings included results from the Phase 2 COCOON study, which demonstrated that a proactive dermatologic regimen improved patient experience by reducing skin-related side effects. The company also presented data from the Phase 2 PALOMA-2 study, which supports the feasibility of switching patients to subcutaneous amivantamab administration.

The results reinforce Johnson & Johnson's focus on developing chemotherapy-free regimens that extend survival and improve the quality of life for lung cancer patients. The findings may reshape treatment discussions and set new standards for EGFR-targeted therapies.

Johnson & Johnson has launched NJBioFutures, a public-private workforce development initiative in collaboration with the New Jersey Council of County Colleges. The program aims to create a skilled talent pipeline for the cell and gene therapeutics sector by developing industry-aligned curricula and training facilities at three community colleges: Raritan Valley Community College, Middlesex College, and Mercer County Community College.

As the founding sponsor, Johnson & Johnson is contributing $1 million to support the initiative, which includes a 22,000-square-foot expansion of the Workforce Training Center at RVCC. The program will provide specialized education and training in advanced manufacturing techniques used in cell and gene therapy.

Company leaders, including Chairman and CEO Joaquin Duato and Chief Technical Operations & Risk Officer Kathy Wengel, joined state officials such as New Jersey First Lady Tammy Murphy and Department of Labor Commissioner Robert Asaro-Angelo to emphasize the importance of workforce development in healthcare innovation.

New Jersey, home to eight of the world’s top ten pharmaceutical companies, is a leader in life sciences. NJBioFutures aims to strengthen the state’s role in biopharmaceutical innovation by preparing the next generation of professionals to tackle major healthcare challenges.

Johnson & Johnson announced that the U.S. FDA has granted Fast Track designation to nipocalimab for the treatment of moderate-to-severe Sjögren's disease, following its previous Breakthrough Therapy designation. Sjögren's disease is a chronic autoimmune condition with no FDA-approved treatments targeting its underlying causes.

The company is actively enrolling patients in the Phase 3 DAFFODIL study to evaluate the therapy’s effectiveness. Earlier Phase 2 results from the DAHLIAS study showed significant improvement in disease activity and a reduction in IgG levels.

Nipocalimab is an investigational monoclonal antibody designed to block FcRn and lower autoantibody levels, potentially benefiting patients with autoimmune and maternal-fetal diseases. The FDA has previously granted the therapy multiple designations, including Fast Track, Orphan Drug, and Breakthrough Therapy status for other conditions.

Johnson & Johnson emphasized its commitment to advancing treatment options for Sjögren's disease and working closely with regulatory authorities. More information is available on the company’s website and through ongoing clinical trials.

Johnson & Johnson MedTech is showcasing its latest advancements in digital orthopaedics at the American Academy of Orthopaedic Surgeons 2025 Annual Meeting. Building on last year’s momentum of 18 FDA 510(k) clearances and 45 global product launches, the company is unveiling innovations in joint reconstruction, trauma, spine, and surgical robotics.

Key highlights include:

- VELYS robotic-assisted solution, a CT-free system that enhances total knee replacements, now approved for unicompartmental knee arthroplasty.
- KINCISE 2 surgical automated system, designed to reduce the physical strain on surgeons during hip and knee procedures.
- VELYS active robotic assistance for spine, a next-generation platform integrating navigation with active robotics for complex spinal surgeries.
- VOLT trauma system, an advanced plating system for fracture stabilization, now expanding into select European markets.
- INHANCE INTACT shoulder replacement, an FDA-cleared solution enabling patients to move their shoulders immediately post-surgery.
- AI-powered advance case management, optimizing surgery preparation and efficiency for outpatient centers.

These innovations aim to improve precision, efficiency, and patient outcomes while reducing surgical burdens. Johnson & Johnson MedTech continues to leverage digital technology to transform orthopaedic care.

Johnson & Johnson has been dedicated to developing treatments for inflammatory bowel disease (IBD) for decades, culminating in the recent FDA approval of a promising new medication for moderate to severe ulcerative colitis (UC). IBD, which includes Crohn’s disease and UC, affects up to 10 million people worldwide and remains without a cure.

The company has pioneered numerous advancements in IBD treatment, from the first biologic therapy in the 1990s to the development of innovative immune-modulating drugs. Their latest therapy, a dual-acting monoclonal antibody, has shown significant symptom improvement and intestinal healing in clinical trials.

Ongoing research focuses on groundbreaking approaches such as mucosal immunology and combination therapies using multispecific antibodies to enhance treatment effectiveness. Johnson & Johnson remains committed to raising the standard of care for IBD patients through continuous innovation.
JNJ

johnson & johnson (nyse: jnj) announced positive topline results from the phase 2b anthem-uc study evaluating icotrokinra (jnj-2113), an investigational targeted oral peptide that blocks the il-23 receptor, in adults with moderately to severely active ulcerative colitis. the study met its primary endpoint, demonstrating clinical response in all dose groups, with the highest dose achieving a response rate of 63.5% at week 12 compared to 27% for placebo. clinical remission was achieved in 30.2% of patients in the highest dose group versus 11.1% for placebo.

icotrokinra was well tolerated, with adverse events occurring at similar rates between treatment and placebo groups. results continued to improve through week 28.

comprehensive results are being prepared for presentation at upcoming medical conferences.

source: johnson & johnson

Johnson & Johnson announced that icotrokinra (JNJ-2113), an investigational oral peptide that blocks the IL-23 receptor, showed promising results in treating moderate-to-severe plaque psoriasis. In the Phase 3 ICONIC-LEAD trial, nearly half (46%) of patients achieved completely clear skin (IGA 0) at 24 weeks, while 65% reached PASI 90. The treatment demonstrated a favorable safety profile, with adverse event rates comparable to placebo.

Additionally, Phase 3 ICONIC-ADVANCE 1&2 trials showed icotrokinra’s superiority over deucravacitinib. Encouraged by these results, Johnson & Johnson is launching ICONIC-ASCEND, the first-ever head-to-head trial comparing an oral pill (icotrokinra) against an injectable biologic (ustekinumab) in psoriasis.

Icotrokinra is being positioned as a potential first-line systemic therapy for psoriasis, offering an effective, convenient alternative to injectables.

Johnson & Johnson has appointed Darren Snellgrove as Vice President of Investor Relations, effective May 1, 2025. He succeeds Jessica Moore, who will become Group Chief Financial Officer for Johnson & Johnson Innovative Medicine. Both will continue reporting to Chief Financial Officer Joseph Wolk. Snellgrove, who has been with the company since 1999, brings extensive financial leadership experience across Innovative Medicine, MedTech, R&D, and Business Development. Moore, who led Investor Relations since 2021, will now oversee financial strategy for Innovative Medicine. The appointments reflect Johnson & Johnson’s commitment to leadership development and long-term strategy.

A new report from PatientView highlights the continued importance of environmental, social, and governance (ESG) policies in shaping patient groups' perceptions of major pharmaceutical companies. Despite declining corporate interest and increasing political opposition to ESG in the U.S., the survey of 701 patient groups found that 94% consider a company's social impact important, followed by 88% prioritizing corporate governance and 67% emphasizing environmental practices.

When ranking 15 major drugmakers on ESG performance, Roche was rated highest overall, followed by Gilead Sciences and Johnson & Johnson Innovative Medicine. Among companies that patient groups have directly partnered with, Gilead took the top spot, followed by Roche and AstraZeneca.

The report also suggests that patient groups want clearer communication and more concrete actions from pharma companies regarding ESG initiatives. While the study underscores ESG's relevance to patient organizations, broader business support for ESG is wavering. A GlobalData survey found that only 8% of people believe ESG will significantly impact their business in the next year, down from 20% in 2022.

In the U.S., ESG has become a contentious issue, with multiple states enacting laws against such policies. PatientView noted that fewer U.S. patient groups participated in this survey compared to past pharma-related studies, likely reflecting the growing controversy surrounding ESG commitments.

Source: Fierce Pharma

Johnson & Johnson (NYSE: JNJ) has completed its previously announced public offerings of $5 billion in aggregate principal amount of senior notes. The offerings include $750 million of 4.500% notes due 2027, $750 million of 4.550% notes due 2028, $1 billion of 4.700% notes due 2030, $1.25 billion of 4.850% notes due 2032, and $1.25 billion of 5.000% notes due 2035. The company entered into an underwriting agreement on February 18, 2025, with Citigroup Global Markets Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC as representatives of the underwriters.

Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the subcutaneous (SC) formulation of RYBREVANT (amivantamab). This formulation is recommended for the first-line treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) in combination with LAZCLUZE (lazertinib) and as monotherapy for patients with EGFR exon 20 insertion mutations after failure of platinum-based therapy.

The Phase 3 PALOMA-3 study demonstrated that SC amivantamab was non-inferior to the intravenous (IV) version in terms of pharmacokinetics, while also reducing infusion-related reactions five-fold and lowering the incidence of venous thromboembolic events. The new administration method reduces infusion time from five hours to just five minutes.

This milestone aligns with Johnson & Johnson’s commitment to enhancing patient experience and treatment accessibility for lung cancer. If approved by the European Commission, the subcutaneous formulation will offer a more convenient and safer alternative for NSCLC patients.

Johnson & Johnson has announced the publication of pivotal Phase 3 study results for nipocalimab, an investigational FcRn blocker, in *The Lancet Neurology*. The Vivacity-MG3 study demonstrated significant and sustained disease control over 24 weeks in antibody-positive adults with generalized myasthenia gravis (gMG). This included up to a 75% reduction in autoantibody levels, a root cause of the disease, with no observed impact on other immune functions. Nipocalimab also showed a tolerable safety profile, with adverse event discontinuation rates comparable to placebo. The investigational therapy has been granted FDA Priority Review for gMG treatment and is currently under review by the European Medicines Agency (EMA).

gMG is a rare, chronic autoantibody-driven neuromuscular disease affecting around 700,000 people globally, with symptoms including muscle weakness, difficulty swallowing, and respiratory challenges. Nipocalimab, a fully human IgG1 monoclonal antibody, selectively reduces IgG autoantibodies that disrupt muscle contractions, potentially addressing the disease's root cause. Johnson & Johnson emphasized the importance of this breakthrough, particularly for patients with limited therapeutic options. The company’s continued commitment to innovative treatments for autoantibody diseases is underscored by nipocalimab's development across multiple conditions, including Sjögren’s disease and hemolytic diseases of the fetus and newborn, further solidifying its potential as a transformative therapy.

Johnson & Johnson announced its fourth-quarter and full-year 2024 financial results, reporting strong sales growth and significant progress in its pipeline of innovative medicines and MedTech solutions. Fourth-quarter sales reached $22.5 billion, a 5.3% increase from the previous year, while full-year sales grew 4.3% to $88.8 billion. Adjusted operational growth excluding the COVID-19 vaccine was 7.0% for the full year.

Key highlights include:

Fourth-quarter performance included reported earnings per share (EPS) of $1.41 and adjusted EPS of $2.04, with a $0.22 impact from acquired in-process research and development (IPR&D) charges related to the V-Wave acquisition.

Full-year performance featured reported EPS of $5.79 and adjusted EPS of $9.98, with a $0.67 impact from acquired IPR&D charges on various transactions. Free cash flow for the year was approximately $19.8 billion.

The Innovative Medicine segment achieved 5.7 percent adjusted operational sales growth, excluding COVID-19 vaccines, driven by products like Darzalex, Tremfya, and Carvykti. The MedTech segment grew by 6.2 percent, supported by strong demand for cardiovascular and wound closure products.

Pipeline advances included U.S. FDA approval of Spravato for treatment-resistant depression, the European Commission's approval of Lazcluze in combination with Rybrevant for advanced non-small cell lung cancer, and progress with Ottava, the company's robotic surgical system.

For 2025, Johnson & Johnson projects operational sales growth of 2.5 to 3.5 percent, with adjusted operational EPS expected to range between $10.75 and $10.95, reflecting an 8.7 percent increase at the midpoint. The company’s commitment to innovation and its robust pipeline positions it to address unmet medical needs across various therapeutic areas.